2,8-二甲基-4-羟基喹啉 | 52481-91-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2,8-二甲基-4-羟基喹啉
• 英文名称: 4-hydroxy-2,8-dimethylquinoline
• 英文别名: 2,8-dimethyl-1H-quinolin-4-one；2,8-dimethyl-1(H)-quinolone-4；2,8-dimethyl-1H-quinolin-4-one；2,8-Dimethylquinolin-4-ol
• CAS: 52481-91-1
• 化学式: C₁₁H₁₁NO
• mdl: MFCD00100264
• 分子量: 173.214
• InChiKey: QUHJYDMHDWSZIP-UHFFFAOYSA-N

物化性质

• 沸点：
  292℃
• 密度：
  1.107
• 闪点：
  125℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,8-Dimethylquinolin-4(1H)-one
Synonyms: 2,8-Dimethyl-4-hydroxyquinoline

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,8-Dimethylquinolin-4(1H)-one
CAS number: 52481-91-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H11NO
Molecular weight: 173.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,8-二甲基-4-羟基喹啉 在 三氯氧磷 作用下， 反应 6.0h， 生成 4-氯-2,8-二甲基喹啉
  参考文献：
  名称：

  [EN] HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES HÉTÉROCYCLIQUES DU RÉCEPTEUR DU CGRP

  摘要：

  本发明涉及杂环化合物，其是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。

  公开号：

  WO2016022645A1
• 作为产物：
  描述：

  ethyl 3-[(2-methylphenyl)amino]but-2-enoate 以 二苯醚 为溶剂， 反应 1.0h， 生成 2,8-二甲基-4-羟基喹啉
  参考文献：
  名称：

  [EN] HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES HÉTÉROCYCLIQUES DES RÉCEPTEURS CGRP

  摘要：

  本发明涉及杂环化合物，其为CGRP受体拮抗剂，可能在治疗或预防涉及CGRP的疾病（如偏头痛）方面有用。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及CGRP的疾病中使用这些化合物和组合物。

  公开号：

  WO2016022644A1

文献信息

• Neue 4-Chinolinol- und 5,6,7,8-Tetrahydro-4-chinolinol-abkömmlinge mit biozider Wirkung
  作者：Horst Gildemeister、Harald Knorr、Hilman Mildenberger、Gerhard Salbeck

  DOI：10.1002/jlac.198219820908

  日期：1982.9.17

  Es wird die Synthese einiger O-substituierter 4-Chinolinole und 5,6,7,8-Tetrahydro-4-chinolinole 7–13 beschrieben. Ausgehend von 2 und 4 gelangt man mit POCl3 zu 4-Chlorchinolinen 14 und 15, welche in die 4-Aryloxychinoline 16 und 17 sowie 4-Alkyl-(Aryl-)thiochinoline 20 bzw. 4-Aminochinoline 21 übergeführt werden.

  描述了一些O-取代的4-喹啉醇和5,6,7,8-四氢-4-喹啉醇7-13的合成。从2和4开始，POCl 3产生4-氯喹啉14和15，它们分别被转化为4-芳氧基喹啉16和17和4-烷基（芳基）硫代喹啉20和4-氨基喹啉21。
• Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
  申请人：——

  公开号：US20030139388A1

  公开（公告）日：2003-07-24

  The present application describes novel cyclic hydroxamic acids of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR 1 , and S(O) p , and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.

  本申请描述了新型的公式I:1的环式羟羧酸，或其药用盐形式，其中环B是一个包含0-2个来自O、N、NR1和S(O)p的杂原子以及0-1个羰基的5-7元环系统，其他变量在本说明书中有定义，这些化合物可作为基质金属蛋白酶（MMP）、TNF-α转化酶（TACE）、聚集素酶或其组合的抑制剂，包含这些化合物的药物组合物，以及使用这些化合物的方法。
• NaHSO₄/SiO₂: An Efficient Catalyst for the Synthesis of β-Enaminones and 2-Methylquinolin-4(1H)-Ones under Solvent-Free Condition
  作者：Suryakant B. Sapkal、Kiran F. Shelke、Bapurao B. Shingate、Murlidhar S. Shingare

  DOI：10.5012/jkcs.2010.54.6.723

  日期：2010.12.20

  An efficient and simplified protocol for NaHSO 4 /SiO 2 catalyzed solvent-free synthesis of β-enaminone and 2-methyl-quinolin-4( 1H)-one derivatives under microwave irradiation is described. A series of functionalized derivatives have been synthesized in shorter reaction times with moderate to good yields. The use of milder catalyst in non-conventional method offers significant advantages over conventional

  描述了一种在微波辐射下NaHSO 4 / SiO 2催化的β-烯胺酮和2-甲基-喹啉-4（1H）-one衍生物的无溶剂合成的有效且简化的方案。已经以较短的反应时间合成了一系列官能化衍生物，具有中等至良好的产率。与常规方法相比，在非常规方法中使用温和的催化剂具有明显的优势，例如更高的选择性，简便性，无溶剂反应和非环境污染条件。
• [EN] HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES HÉTÉROCYCLIQUES DES RÉCEPTEURS CGRP
  申请人：MERCK SHARP & DOHME

  公开号：WO2016022644A1

  公开（公告）日：2016-02-11

  The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and may be useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及杂环化合物，其为CGRP受体拮抗剂，可能在治疗或预防涉及CGRP的疾病（如偏头痛）方面有用。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及CGRP的疾病中使用这些化合物和组合物。
• [EN] HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES HÉTÉROCYCLIQUES DU RÉCEPTEUR DU CGRP
  申请人：MERCK SHARP & DOHME

  公开号：WO2016022645A1

  公开（公告）日：2016-02-11

  The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及杂环化合物，其是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。

表征谱图